论文部分内容阅读
１２例健康志愿者随机交叉口服进口尼莫地平普通片和尼莫地平缓释胶囊６０ｍｇ后，利用高效液相色谱法测定血药浓度并对其生物利用度进行了研究。尼莫地平缓释胶囊和进口片的Ｔ_ １／２。分别为３．７４± ０．８４ ｈ和１．９８± ０．５９ ｈ；Ｃ_ｍａｘ分别为２５．４１±９．３２μｇ Ｌ~－１和８０．０８±１６．６５ μｇ·Ｌ~－１；Ｔ_ｍａｘ分别为３．２５±０．９７ ｈ和０．７５±０．２１ｈ；Ａ ＵＣ分别为 １６７．４±２７．３ μｇ· ｈ· Ｌ~ －１和１９４．７± ２９．７μｇ· ｈ· Ｌ~－１；缓释胶囊的相对生物利用度为 ８７．０７％ ± ９．１９％。 ８例健康志愿者随机交叉多剂量口服尼莫地平缓释胶囊（６０ ｍｇ，ｂｉｄ）和尼莫地平普通片（３０ ｍｇ，ｑｉｄ），达稳态时测得峰浓度分别为２５．８１± ７．１２ μｇ· Ｌ~ －１和 ４１．２１± １０．０４ μｇ· Ｌ~－１；谷浓度分别为 ７．１９ ±１．８４ μｇ· Ｌ~－１和５．５９ ±１． ６２ μｇ·Ｌ~－１；两者血药浓度的波动系数分别为１．１２ ± ０．１６和１．５１± ０．１７。
Twelve healthy volunteers were randomly assigned to oral administration of nimodipine and nimodipine sustained release capsules 60mg, the use of high performance liquid chromatographic determination of plasma concentration and bioavailability were studied. Nimodipine Sustained Release Capsule and Imported T_ 1/2. Respectively, 3.74 ± 0.84 h and 1.98 ± 0.59 h; C_max were 25.41 ± 9.32 μg L ~ -1 and 80.08 ± 16.65 μg · L ~ Respectively, 3.25 ± 0.97 h and 0.75 ± 0.21 h; A UC were 167.4 ± 27.3 μg · h · L -1 and 194.7 ± 29.7 μg · h · L ~ -1. The relative bioavailability of sustained release capsules was 87.07% ± 9.19%. 8 healthy volunteers were randomized crossover and multi-dose oral administration of nimodipine sustained-release capsules (60 mg bid) and nimodipine common tablets (30 mg qid). The peak concentrations at steady state were 25.81 ± 7 .12 μg · L -1 and 41.21 ± 10.04 μg · L -1, respectively. The trough concentrations were 7.19 ± 1.84 μg · L -1 and 5.59 ± 1, respectively. 62 μg · L ~ (-1); the fluctuation coefficients of plasma concentrations of the two drugs were 1.12 ± 0.16 and 1.51 ± 0.17 respectively.